ESR1 and breast cancer: In this case, TSA inhibited HDAC, enhanced the re-expression of ERα in MDA-MB-231 cells, induced re-sensitization and reactivation of ERα-negative breast cancer cells to E2 and tamoxifen (TAM) antagonist, and promoted histone-remodeling changes in the ERα promoter [49,228,229].